Popular Articles

ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect On Pandemic H1N1 Influenza Virus After Oral Administration
ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.

Mind Welcomes Radical Reform Of Social Care, UK
As the Government sets out proposals to reform social care, leading mental health charity Mind welcomes the move to simplify the process and create a fairer system for the many thousands of people with mental health problems who currently pay for social care services.
News of the day
UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323
UCB and Biogen Idec announced the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted.
Public Health

New Study Uncovers Mode Of Action Of Enzyme Linked With Several Types Of Cancer

Scientists at the Institute for Research in Immunology and Cancer (IRIC) of the Universitçİ de Montrçİal have discovered a key mechanism used by cells to efficiently distribute chromosomes to new cells during cell multiplication. Published in the journal Molecular Cell, the study is the first to demonstrate that this mechanism relies on the polo kinase, an enzyme implicated in several cancers. Inhibiting this mechanism could be key to developing effective therapies to treat cancer. Each human cell contains, in its nucleus, all the coding instructions necessary to direct the cell"s activities. A complete set of those instructions is referred to as a genome. Cancer cells are capable of altering their genome in order to promote uncontrolled growth. "Cancer cells achieve this by gaining or losing specific chromosomes, or by inducing structural defects in their genome," explains Damien D"Amours, Principal Investigator at IRIC and director of the study, "We discovered that the polo kinase, overexpressed in a broad range of human tumours, tells the chromosomes exactly when to condense during cell division." Misregulation of the polo kinase is associated with cancers, thereby suggesting a link between defects in chromosome condensation and the formation of tumours. "Pharmaceutical companies and independent researchers are already working on the development of new cancer drugs to inhibit the activity of the polo kinase," points out Damien D"Amours, "Understanding this enzyme"s mode of action should enable us to control it. Such knowledge may reveal itself to be key in developing effective therapies to treat cancer." In a preview article commissioned by Molecular Cell, world leader in chromosome dynamics Tatsuya Hirano, of the Riken Advanced Science Institute in Japan, qualifies the research as a tour de force study that will help address outstanding questions in the field. Carolyne Lord University of Montreal


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):